Drugs / Enteric-coated aspirin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT02834403 Background | Nov 2016 → Jan 2021 | triple-negative breast carcinoma | The Methodist Hospital Research Institute | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Enteric-coated aspirin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02834403 ↗ |
| Route | Oral | “amlodipine (10 mg) and enteric-coated low-dose aspirin (81 mg) will be orally administered” NCT02834403 ↗ |